Brilinta (Ticagrelor) Patent Expiration, LOE Window & CMS Spending
Brilinta (Ticagrelor) by AstraZeneca: FDA Orange Book LOE 2036-07-27, 20 AB generics, $812.0M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AstraZeneca |
| FDA Application & Pathway | N022433 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2036-07-27 |
| Orange Book Patents (*PED Extensions) | 4 patents (2 *PED) |
| Active AB-Rated Generic Competitors | 20 |
| 2024 CMS Total Public Spend | $812.0M |
| 2024 Medicare Part D Spend | $685.5M |
| 2024 Medicaid Spend | $126.6M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.